Alkermes plc. Discontinued Operation, Tax Effect of Discontinued Operation
Alkermes plc. (ALKS) reported Discontinued Operation, Tax Effect of Discontinued Operation of -$722.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation · last filed 2026-02-25
- Alkermes plc. discontinued operation, tax effect of discontinued operation for the quarter ending 2024-12-31 was $354.00K, a 94.88% decline year-over-year.
- Alkermes plc. discontinued operation, tax effect of discontinued operation for the quarter ending 2024-09-30 was -$67.00K.
- Alkermes plc. discontinued operation, tax effect of discontinued operation for the quarter ending 2024-06-30 was -$613.00K.
- Alkermes plc. discontinued operation, tax effect of discontinued operation for the quarter ending 2024-03-31 was -$396.00K.
- Alkermes plc. discontinued operation, tax effect of discontinued operation for fiscal 2024 was -$722.00K.
- Alkermes plc. discontinued operation, tax effect of discontinued operation for fiscal 2023 was -$1.40M.
| Period end | Discontinued Operation, Tax Effect of Discontinued Operation 3 month | Discontinued Operation, Tax Effect of Discontinued Operation 6 month | Discontinued Operation, Tax Effect of Discontinued Operation 9 month | Discontinued Operation, Tax Effect of Discontinued Operation 12 month |
|---|---|---|---|---|
| 2024-12-31 | $354.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $287.00K derived: sum of 2 quarters · filed 2026-02-25 | -$326.00K derived: sum of 3 quarters · filed 2026-02-25 | -$722.00K 10-K · filed 2026-02-25 |
| 2024-09-30 | -$67.00K 10-Q · filed 2025-10-28 | -$680.00K derived: sum of 2 quarters · filed 2025-10-28 | -$1.08M 10-Q · filed 2025-10-28 | $5.84M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$613.00K 10-Q · filed 2025-07-29 | -$1.01M 10-Q · filed 2025-07-29 | $5.91M derived: sum of 3 quarters · filed 2026-02-25 | $4.36M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$396.00K 10-Q · filed 2025-05-01 | $6.52M derived: sum of 2 quarters · filed 2026-02-25 | $4.97M derived: sum of 3 quarters · filed 2026-02-25 | $4.93M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $6.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $5.36M derived: sum of 2 quarters · filed 2026-02-25 | $5.32M derived: sum of 3 quarters · filed 2026-02-25 | -$1.40M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$1.55M 10-Q · filed 2024-10-24 | -$1.59M derived: sum of 2 quarters · filed 2024-10-24 | -$8.32M 10-Q · filed 2024-10-24 | |
| 2023-06-30 | -$40.00K 10-Q · filed 2024-07-24 | -$6.77M 10-Q · filed 2024-07-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |